Hangzhou Tigermed Consulting Co., Ltd.

HKSE 3347.HK

Hangzhou Tigermed Consulting Co., Ltd. Return on Capital Employed (ROCE) for the year ending December 31, 2023: 10.21%

Hangzhou Tigermed Consulting Co., Ltd. Return on Capital Employed (ROCE) is 10.21% for the year ending December 31, 2023, a 12.25% change year over year. Return on capital employed assesses profitability against invested capital; higher ROCE signals efficient capital use.
  • Hangzhou Tigermed Consulting Co., Ltd. Return on Capital Employed (ROCE) for the year ending December 31, 2022 was 9.10%, a 1.12% change year over year.
  • Hangzhou Tigermed Consulting Co., Ltd. Return on Capital Employed (ROCE) for the year ending December 31, 2021 was 9.00%, a 47.23% change year over year.
  • Hangzhou Tigermed Consulting Co., Ltd. Return on Capital Employed (ROCE) for the year ending December 31, 2020 was 6.11%, a -68.94% change year over year.
  • Hangzhou Tigermed Consulting Co., Ltd. Return on Capital Employed (ROCE) for the year ending December 31, 2019 was 19.67%, a -3.40% change year over year.
Key data
Date Return on Capital Employed (ROCE) Interest Coverage Ratio Debt to Equity Ratio Return on Common Equity
Market news
Loading...
SV Wall Street
HKSE: 3347.HK

Hangzhou Tigermed Consulting Co., Ltd.

CEO Dr. Xiaoping Ye D.Phil, EMBA, M.D., Ph.D.
IPO Date Aug. 7, 2020
Location China
Headquarters F18, Building A – Shengda Science Park
Employees 9,701
Sector Industrials
Industries
Description

Hangzhou Tigermed Consulting Co., Ltd. provides contract research organization services in the People's Republic of China and internationally. It operates in Clinical Trial Solutions, and Clinical-related and Laboratory Services segments. The company offers regulatory submission and approval, medical translation, and good manufacturing practice (GMP) consulting services; and clinical services in the areas of medical science, early clinical and late phase development, medical monitoring, project management, patient recruitment, and quality management system. It also provides biometrics services comprising data management, biostatistics, and statistical programming; and integrated technology services, such as site management, pharmacovigilance, third party audit and training, medical imaging, clinical trial system solution, central laboratory, pre-clinical, and research hospital. Further, the company offers medical device/ in vitro diagnostics (IVD) services comprising medical device testing, regulatory submission, clinical evaluation and trials, GMP certificate, EU MDR and IVDR preparation, and value-added services; and post-marketing study, real world evidence, and vaccine clinical trial services. Hangzhou Tigermed Consulting Co., Ltd. was incorporated in 2004 and is headquartered in Hangzhou, the People's Republic of China.

Similar companies

2359.HK

WuXi AppTec Co., Ltd.

USD 7.19

0.25%

3759.HK

Pharmaron Beijing Co., Ltd.

USD 1.84

0.83%

1801.HK

Innovent Biologics, Inc.

USD 4.24

1.99%

9926.HK

Akeso, Inc.

USD 7.68

-4.49%

StockViz Staff

January 31, 2025

Any question? Send us an email